FDA — authorised 19 April 2019
- Application: ANDA206430
- Marketing authorisation holder: HIKMA
- Status: approved
FDA authorised Intravesical Solution on 19 April 2019
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 19 April 2019; FDA has authorised it.
HIKMA holds the US marketing authorisation.